Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis)

References

• LubbertsETh17 cytokines and arthritisSemin Immunopathol201032435320127485
   PubMed Web of Science ®Google Scholar
• YaoZPainterSLFanslowWCHuman IL-17: a novel cytokine derived from T cellsJ Immunol1995155548354867499828
   PubMed Web of Science ®Google Scholar
• HarringtonLEHattonRDManganPRInterleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineagesNat Immunol200561123113216200070
   PubMed Web of Science ®Google Scholar
• ParkHLiZYangXOA distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17Nat Immunol200561133114116200068
   PubMed Web of Science ®Google Scholar
• McGeachyMJBak-JensenKSChenYTGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathologyNat Immunol200781390139717994024
   PubMed Web of Science ®Google Scholar
• YangXOPappuBPNurievaRT helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gammaImmunity200828293918164222
   PubMed Web of Science ®Google Scholar
• LangrishCLMcKenzieBSWilsonNJIL-12 and IL-23: master regulators of innate and adaptive immunityImmunol Rev20042029610515546388
   PubMed Web of Science ®Google Scholar
• KasteleinRAHunterCACuaDJDiscovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammationAnnu Rev Immunol20072522124217291186
   PubMed Web of Science ®Google Scholar
• HoeveMASavageNDde BoerTDivergent effects of IL-12 and IL-23 on the production of IL-17 by human T cellsEur J Immunol20063666167016482511
   PubMed Web of Science ®Google Scholar
• LaurenceATatoCMDavidsonTSInterleukin-2 signaling via STAT5 constrains T helper 17 cell generationImmunity20072637138117363300
   PubMed Web of Science ®Google Scholar
• AwasthiACarrierYPeronJPA dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cellsNat Immunol200781380138917994022
   PubMed Web of Science ®Google Scholar
• WeaverCTHattonRDManganPRHarringtonLEIL-17 family cytokines and the expanding diversity of effector T cell lineagesAnnu Rev Immunol20072582185217201677
   PubMed Web of Science ®Google Scholar
• SteffenCWilliam John Munro and Munro’s abscess, and Franz Kogoj and Kogoj’s spongiform pustuleAm J Dermatopathol20022436436812142621
   PubMed Web of Science ®Google Scholar
• SchonMDenzerDKubitzaRCRuzickaTSchonMPCritical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin miceJ Invest Dermatol200011497698310771480
   PubMed Web of Science ®Google Scholar
• CaiYShenXDingCPivotal role of dermal IL-17-producing gammadelta T cells in skin inflammationImmunity20113559661021982596
   PubMed Web of Science ®Google Scholar
• CicciaFGugginoGRizzoAType 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitisAnn Rheum Dis2015 pii:annrheumdis-2014-206323
   Web of Science ®Google Scholar
• YenDCheungJScheerensHIL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6J Clin Invest20061161310131616670770
   PubMed Web of Science ®Google Scholar
• LiangSCTanXYLuxenbergDPInterleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptidesJ Exp Med20062032271227916982811
   PubMed Web of Science ®Google Scholar
• MaHLLiangSLiJIL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammationJ Clin Invest200811859760718202747
   PubMed Web of Science ®Google Scholar
• CauliAYanniGPanayiGSInterleukin-1, interleukin-1 receptor antagonist and macrophage populations in rheumatoid arthritis synovial membraneBr J Rheumatol1997369359409376987
   PubMedGoogle Scholar
• CauliAPitzalisCYanniGHawadMPanayiGSCD1 positive antigen presenting cells in psoriatic and rheumatoid arthritisRheumatology2000666667310888713
   PubMed Web of Science ®Google Scholar
• PitzalisCCauliAPipitoneNCutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritisArthritis Rheum1996391371458546722
   PubMed Web of Science ®Google Scholar
• CauliADessoleGFiorilloMTAIncreased level of HLA-B27 expression in ankylosing spondylitis patients compared with healthy HLA-B27-positive subjects: a possible further susceptibility factor for the development of diseaseRheumatology2002411375137912468816
   PubMed Web of Science ®Google Scholar
• CauliADessoleGVaccaASusceptibility to ankylosing spondylitis but not disease outcome is influenced by the level of HLA-B27 expression, which shows moderate variability over timeScand J Rheumatol20124121421822360441
   PubMed Web of Science ®Google Scholar
• LiuYHelmsCLiaoWA genome-wide association study of psoriasis and psoriatic arthritis identifies new disease lociPLoS Genet20084e100004118369459
   PubMed Web of Science ®Google Scholar
• NairRPRuetherAStuartPEPolymorphisms of the IL12B and IL23R genes are associated with psoriasisJ Invest Dermatol20081281653166118219280
   PubMed Web of Science ®Google Scholar
• Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC)BurtonPRAssociation scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variantsNat Genet2007391329133717952073
   PubMed Web of Science ®Google Scholar
• DuerrRHTaylorKDBrantSRA genome-wide association study identifies IL23R as an inflammatory bowel disease geneScience20063141461146317068223
   PubMed Web of Science ®Google Scholar
• LeeETrepicchioWLOestreicherJLIncreased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgarisJ Exp Med200419912513014707118
   PubMed Web of Science ®Google Scholar
• SzodorayPAlexPChappell-WoodwardCMCirculating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array systemRheumatology20074641742516936328
   PubMed Web of Science ®Google Scholar
• KotakeSUdagawaNTakahashiNIL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesisJ Clin Invest19991031345135210225978
   PubMed Web of Science ®Google Scholar
• SatoKSuematsuAOkamotoKTh17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destructionJ Exp Med20062032673268217088434
   PubMed Web of Science ®Google Scholar
• FujinoSAndohABambaSIncreased expression of interleukin 17 ininflammatory bowel diseaseGut200352657012477762
   PubMed Web of Science ®Google Scholar
• AnnunziatoFCosmiLSantarlasciVPhenotypic and functional features of human Th17 cellsJ Exp Med20072041849186117635957
   PubMed Web of Science ®Google Scholar
• BownessPRidleyAShawJTh17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitisJ Immunol20111862672268021248258
   PubMed Web of Science ®Google Scholar
• CauliAShawJGilesJThe arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B*27:09Rheumatology2013521952196223804219
   PubMed Web of Science ®Google Scholar
• GenoveseMCDurezPRichardsHBEfficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, doubleblind, randomised, placebo controlled studyAnn Rheum Dis20137286386922730366
   PubMed Web of Science ®Google Scholar
• PappKALangleyRGLebwohlMEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Lancet20083711675168418486740
   PubMed Web of Science ®Google Scholar
• McInnesIBKavanaughAGottliebABEfficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialLancet201338278078923769296
   PubMed Web of Science ®Google Scholar
• KavanaughARitchlinCRahmanPUstekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trialsAnn Rheum Dis2014731000100624553909
   PubMed Web of Science ®Google Scholar
• PodubbnyyDCallhoffJListingJUstekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)Arthritis Rheumatol20136510 (Suppl)S766
   Google Scholar
• LangleyRGElewskiBELebwohlMSecukinumab in plaque psoriasis – results of two phase 3 trialsN Engl J Med201437132633825007392
   PubMed Web of Science ®Google Scholar
• van der HeijdeDLandeweRMeasePSecukinumab, a monoclonal antibody to interleukin-17A, provides significant and sustained inhibition of joint structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, double-blind, placebo-controlled studyArthritis Rheum201466SupplS424 Abstract 954
   Google Scholar
• McInnesIBMeasePKirkhamBSecukinumab, a human anti-interleukin-17A monoclonal antibody, improves active psoriatic arthritis: 24-week efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study using subcutaneous dosingLate breaking oral presentation at ACR/ARHP Annual MeetingBoston, MA, USA2014 Presentation number L1
   Google Scholar
• BaetenDBraunJBaraliakosXSecukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a 52-week phase 3 randomized placebo-controlled trial with intravenous loading and subcutaneous maintenance dosingArthritis Rheum201466SupplS360 Abstract 819
   Google Scholar
• SieperJBraunJBaraliakosXSecukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a phase 3, randomized, placebo-controlled trial with subcutaneous loading and maintenance dosingArthritis Rheum201466SupplS232 Abstract 536
   Google Scholar
• MeasePJGenoveseMCGreenwaldMWBrodalumab, an anti-IL17 RA monoclonal antibody, in psoriatic arthritisN Engl J Med20143702295230624918373
   PubMed Web of Science ®Google Scholar
• PappKALeonardiCMenterABrodalumab, an antiinterleukin-17-receptor antibody for psoriasisN Engl J Med20123661181118922455412
   PubMed Web of Science ®Google Scholar
• MartinDAChurchillMFlores-SuarezLA phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritisArthritis Res Ther201315R16424286136
   PubMed Web of Science ®Google Scholar
• PavelkaKChonYNewmarkRA study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexateJ Rheumatol20154291291925877498
   PubMed Web of Science ®Google Scholar